VRCA Nov 2024 12.500 call
- GlobeNewswire
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States - YCANTH is the only commercially available, FDA approved therapy for molluscum contagiosum and is clinically proven to be safe and effective WEST CHESTER, Pa., July 01, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the settlement of lit
- Simply Wall St.
High Insider Ownership Growth Stocks On US Exchange For June 2024
As the U.S. stock market experiences fluctuations, with recent slips in major indices like the Dow Jones, S&P 500, and Nasdaq from record highs, investors are keenly observing market dynamics and economic indicators such as inflation rates and interest rate expectations. In this context, examining growth companies with high insider ownership might offer valuable insights, as these firms often demonstrate a strong alignment between management's interests and shareholder returns.
- Simply Wall St.
Recent 12% pullback would hurt Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders
Key Insights Insiders appear to have a vested interest in Verrica Pharmaceuticals' growth, as seen by their sizeable...
